The Art and Science of Drug Hunting | Christoph Lengauer, CSO & Co-Founder of Curie.bio

Table Alignment

Host	Sam Kessel and Anastasia Janas
Listen	Apple Podcasts Spotify
Watch	YouTube

Summary

In this episode, we sit down with Christoph Lengauer, co-founder of Curie.Bio, a venture creation firm, and former founding CSO and Chief Drug Hunter at Blueprint Medicines.

Christoph's non-linear career began in Austria as the first in his family to attend college, leading him to pursue human genetics after reading a book on cancer. Despite finding success in academia, he quit science, only to return with a focus on creating medicines, which he considers the ultimate impact. This pivot led him to the best molecular genetics cancer lab in the world, the lab of Bulgin at Johns Hopkins, where he stayed for 12 years and helped lead the lab for nine.

Christoph shares his philosophy on "responsible practice" in drug discovery, a path that avoids the slow, "fat way" of big pharma and the reckless "slim way," by taking measured risks and doing only the necessary work to get to meaningful results the fastest. He argues that successful drug hunting is found in the "margin," defined by cultural elements such as being honest, humble, and transparent, and being surrounded by a supportive team, not just technical strength or intelligence.

We dig into his time at Third Rock Ventures, where he broadened his approach from a narrow focus on kinases to diversifying drug discovery across different target classes and therapeutic areas, and how this experience informed the creation of Curie.Bio. He explains Curie.Bio's model, which centers on freeing the founders, operating with low fixed costs, and providing fractional access to over 100 experienced drug hunters, helping companies like Forward Therapeutics reach the clinic in approximately three years.

Finally, Christoph offers practical advice for founders operating in challenging market environments: have a clear trajectory towards "meaningful clinical activity data" using a $7 million to $15 million budget to reach a development candidate, and an additional $30 million to $50 million to reach that data. He stresses that the biggest mistake a founder can make is thinking they can succeed alone. He advises academic founders to avoid being secretive, to share their ideas with trusted people, and to explain their ideas in "plain English" to clearly articulate the problem they are solving.